Rebecca B Perkins, Richard S Guido, Philip E Castle, David Chelmow, Mark H Einstein, Francisco Garcia, Warner K Huh, Jane J Kim, Anna-Barbara Moscicki, Ritu Nayar, Mona Saraiya, George F Sawaya, Nicolas Wentzensen, Mark Schiffman
This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results...
January 1, 2024: Journal of Lower Genital Tract Disease